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Abstract 
BACKGROUND: Tau protein, along with its phosphorylated forms (pTau), is one of the established 
cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD), but virtually nothing is known about a 
potential diagnostic role of non-phosphorylated tau molecules (Non-P-Tau) in CSF. 
OBJECTIVE: To establish, and analytically and clinically validate the first assay capable to measure 
concentrations of Non-P-Tau in human CSF. 
METHODS: An antibody (1G2) was developed that selectively binds to the non-phosphorylated tau 
molecule at positions 175, 181, and 231, and was used for establishing an ELISA capable to measure 
Non-P-Tau in human CSF. In the analytical validation, linearity, repeatability of the standard curves, and 
intra- and interassay precision of the assay were tested, as well as inter-center variability with the QC 
samples sent either frozen or under ambient temperature. In the clinical part, concentrations of Non-P-Tau 
were measured in CSF samples from carefully selected AD or mild cognitive impairment (MCI) patients, 
whose diagnoses were supported by the results of the "classic" CSF biomarkers (n=58), and as well as in 
CSF samples from non-demented controls (n=42). 
RESULTS: The 1G2 antibody reacts with decreasing reactivity to tau peptides containing 
phosphorylation at positions T175, T181 and T231. The average OD of the blank sample was 0.067 ± 
0.006; the CV's of the optical densities of the repeated standard curves were between 3.6 - 15.9%. Median 
intra-assay range-to-average imprecision of double measurements was 4.8%; inter-assay imprecision of 
was in the range of 11.2% - 15.3%. Non-P-Tau concentrations are stabile in the CSF samples sent to 
distinct laboratories under ambient temperature; inter-laboratory variation was approximately 30%. The 
Non-P-Tau CSF concentrations were highly significantly increased in the AD/MCI group (109.2 ± 32.0 
pg/mL) compared to the Controls (62.1 ± 9.3 pg/mL, p<0.001). At the cut-off of 78.3 mg/mL, the 
sensitivity and the specificity were 94.8% and 97.6%, respectively. 
CONCLUSIONS: For the first time, an assay is reported to reliably measure CSF concentrations of non-
phosphorylated tau. 
 
 
Introduction 
A crucial role of the cerebrospinal fluid (CSF) biomarkers in an early diagnosis of Alzheimer's disease 
(AD) has been extensively discussed, leading to inclusion of the Neurochemical Dementia Diagnostics 
(NDD) biomarkers into different diagnostic and/or research criteria [1-3] + Dubois-IWG. Such 
development is not surprising when considering the need for a reliable early AD diagnosis in clinical 
trials and practice. Research on medical interventions in AD focuses on the early stages of the disorder, 
for example mild cognitive impairment (MCI), and hence CSF biomarkers would be helpful to identify 
individuals in the pre-dementia phase of AD [4]. This was also reflected in the European Medicines 
Agency (EMA) statement that AD CSF biomarkers are useful for the enrichment of the prodromal AD 
populations in clinical trials [5].  
 Alterations in the CSF occur many years or even decades before the onset of the clinical 
symptoms of AD [6, 7]. Currently two groups of molecules in the CSF are accepted as NDD biomarkers: 
amyloid β (Aβ) peptides, which reflect deposition of Aβ (senile) plaques in the brain, and tau protein 
along with its hyperphosphorylated forms (pTau), which is linked to the accumulation of neurofibrillary 
tangles and neurodegeneration (reviewed in ). Although alterations in Aβ metabolism are currently 
considered the earliest detectable events in AD [6], intervention strategies based on the Aβ hypothesis 
have been so far disappointing [8, 9]. This calls for more extensive investigation of other hypotheses, of 
which those related to tau seem particularly attractive [10]. This is further supported by the observation 
that cognitive symptoms in AD are directly related to biomarkers of neurodegeneration rather than 
biomarkers of Aβ deposition (reviewed in [6]); also in neuropathologic studies a clear correlation was 
shown between the degree of neurofibrillary tangle pathology post mortem and a patient's cognitive 
functions intra vitam [11, 12]. 
 Whereas the diagnostic role of tau and its phosphorylated forms, in particular those 
phosphorylated at threonine 181 (pTau181), has been extensively studied in the last decade, we are not 
aware of any study addressing the diagnostic role of CSF non-phosphorylated tau epitopes (Non-P-Tau); 
furthermore, we have not found any reports of an assay capable to specifically measure CSF 
concentrations of Non-P-Tau. Hence it seemed relevant to establish such an assay and to investigate 
whether Non-P-Tau could be interesting as a potential novel biomarker of AD. 
 
Materials and Methods 
1. Preparation of phosphorylated aggregated tau 
2mg/500µl recombinant human tau (2N4R isoform 441 amino acids) was  incubated for 20h with 3µg 
activated MAPK13 (Life Technologies, USA) in 10 mM Tris (pH 7.4), 11 mM MgCl2, 1 mM EGTA, 1 
mM DTT, 1mM AEBSF, 0.5 mM Na3VO4, 0.01% TritonX-100, 1 mM ATP at 30°C. Fresh ATP was 
supplemented after 10h incubation. Tau aggregation was started by adding 20fold-aggregation mix (1M 
MOPS pH 6.5, 1M NaCl, 8mg/ml Heparin, 2mM AEBSF) after heat inactivation of MAPK13 and 
phosphorylated tau was incubated 48h at 37°C. Monomeric (fraction 45-47) and aggregated 
phosphorylated tau protein (fractions 21-23) were separated using a Sephacryl S500 gelfiltration column 
as described by [13]. 
 
2. Immunisation and antibody development 
Fifty µg of phosphorylated and aggregated Tau441 in complete Freud adjuvant (Sigma-Aldrich, USA) 
were used for the first immunization of Balb/c mice by subcutaneous injection. Thereafter animals were 
immunized 4 x using incomplete Freud adjuvant during 56 days followed by 3 x intravenous booster 
injections of antigen in 0.02 M phosphate buffered saline pH 7.4 (PBS). Spleen cells were collected and 
fused to mouse myeloma cells X63Ag8.653 using PEG 1500 (Roche Diagnostic GmbH, Mannheim, 
Germany). Fused cells were selected using Hypoxanthine-Aminopterin-Thymidine (HAT) medium 
(Sigma-Aldrich) with Hybridoma Fusion and Cloning Supplement (HFCS) (Roche) during 14 days. 
Clones were selected regarding their reactivity to Tau441 and their IgG production. A clone producing 
monoclonal antibody 1G2 could be selected and were re-cloned twice using the limiting dilution method. 
The antibody was tested for reactivity to tau isoforms (rPeptide, USA) in Western Blot, for reactivity to 
tau and tau fragments in ELISA and Western Blot and to tau peptides not phosphorylated and 
phosphorylated at amino acids 175, 181, 199, 202, 231 and 235 of Tau441 in ELISA. Inhibition 
experiments using peptides of Tau441 containing amino acids 175, 181 and 231 not phosphorylated and 
phosphorylated were performed on Tau441 coated ELISA plates as described by Kovacs et al. (2012). 
Antibody isotype was determined using mouse immunoglobulin isotyping strip test (Roche, Suisse). 
Epitope mapping was performed using 12 amino acid peptides of Tau441 as described by [14]. 
 
3. Development of Sandwich-ELISA for detection of none phosphorylated Tau  
Maxisorb®plates (Thermo Scientific, USA) were coated with 5µg/ml 1G2 antibody in 0.05 mol/l 
Na2CO3/NaHCO3, pH 9.6 with 120 µl per well at 4-8°C overnight. Coated plates were aspirated and 
blocked using 50 mM Tris buffer pH 7.5 containing 0.15 M NaCl and 0.05% Tween 20 (washing buffer) 
containing 3 % BSA fraction V (Serva, Heidelberg, Germany). Using different concentrations of Tau441 
(rPeptide) lyophilized standards and controls were designed by means of dilution buffers containing  BSA 
fraction V (Serva) and skim milk powder (Carl Roth, Germany) basing on phosphate buffered saline 
containing Tween 20 as detergent. The assay was developed studying different incubation protocols and 3 
h room temperature on orbital shaker was found appropriate for antigen binding as first step. Washing 
was performed 5 times using 50 mM Tris buffer pH 7.5 containing 0.15 M NaCl and 0.05% Tween 20 
and followed by 90 min incubation with HRP conjugated detection antibody 7E5 (Analytik Jena AG, 
Germany) at room temperature that binds Tau441 between amino acids 156-165. After additionally  5 
times washing TMB staining was performed by means of ready to use staining solution for 30 min in the 
dark followed by termination with 1.5 M H2SO4.  Optical density was measured at 450nm as well as 
450/620 nm.  
 
 
4. Determination of the intra- and inter-assay imprecision; repeatability of the standard curves 
Intra-assay imprecision was calculated from the duplicate analyses of one hundred CSF samples, and 
expressed as median of the range-to-average of the duplicates. 
Inter-assay imprecision was determined with three quality control (QC) samples prepared from the pooled 
human CSF samples. Briefly, CSF pools were stored at -80°C, and thawed once for the preparation of the 
three QC samples (coded QC1, QC2, and QC3) for this study. After the preparation, aliquots were re-
frozen and kept at -80°C. Immediately before the analysis, one set of the three QC samples was freshly 
thawed. The samples were assayed on eight ELISA plates on eight different days, by the same operator. 
The readings of the optical densities (OD's) were performed in two modes: (A) without the reference 
wavelength (i. e. measurement at 450 nm only) and (B) with the subtraction of the OD's obtained at the 
reference wavelength (620 nm). The imprecision for each QC sample is expressed as the percentage 
coefficients of variation (CV's) defined as the standard deviation divided by the average of eight 
measurements.  
To test repeatability of the standard curves, six independent runs were performed on six different days.  
 
5. Inter-center quality control 
For the inter-center study, four pairs of pooled CSF samples were prepared; from each pair, each of the 
nine participating centers received one aliquot frozen on dry ice and one aliquot shipped at ambient 
temperature. The latter had to be deep frozen upon arrival and kept at -80°C until the analyses. The 
participating centers were informed that they would receive eight samples (four frozen and four in liquid 
status) but not that the frozen and liquid samples are matched. 
 
6. Clinical validation: Patients and samples handling  
The study on the human samples was approved by the ethical committee of the University of Erlangen-
Nürnberg. All patients, or their close relatives, gave their written informed consents. For the clinical 
validation, the analyses were performed in the CSF samples from very carefully selected and 
characterized patients with Alzheimer's Disease (AD) or Mild Cognitive Impairment with AD pathology 
(MCI-AD) (Positive Group, n=58) and Non Demented Controls (Control Group, n=42). AD/MCI patients 
were diagnosed and sub-classified according to the current recommendations from the NIA-AA working 
groups [1, 2], including analyses of the "classic" four AD biomarkers: Aβ1-42, Aβ42/40 ratio, Tau, and 
pTau181. The characteristics of the groups are presented in table 1. The samples were collected by lumbar 
puncture (LP) into polypropylene test tubes according to a protocol described elsewhere [15], centrifuged, 
aliquoted, and stored at -80°C until the analyses. 
 
7. Statistical analysis 
If not stated otherwise, the results are presented as averages ± standard deviations (SD's). Imprecision is 
reported as coefficients of variation (CV's) or as ranges-to-averages (in case of duplicate determinations). 
The area under the receiver operating characteristic (ROC) curve is reported with the corresponding 95% 
confidence interval (95% CI). Statistical comparison of the patient groups was done with the Mann-
Whitney test. The cut off for the separation of the patient groups, and the corresponding sensitivity and 
the specificity, were calculated at the maximized Youden Index. The analyses were performed with 
Statistica and MedCalc. A p<0.05 was considered significant. 
 
Results 
1. Analytical selectivity; intra- and inter-assay imprecision 
Figure 1 presents schematically the tau molecule with the epitopes addressed in this study as well as the 
corresponding kinases known to phosphorylate them [16-18].  
 Antibody 1G2 was determined as IgG2b isotype. Epitope mapping (Fig. 2) shows binding sites of 
1G2 to peptide sequences KTTP (174-177), KTTP (180-183) and RTTP (230-233). The antibody reacts 
in manner of decreasing reactivity to tau peptides containing phosphorylations at positions T175, T181 
and T231 (Fig. 3a). Binding of 1G2 to Tau441 coated ELISA plates (100 ng/ml) was most decreased by 
adding tau peptides containing all three binding sites whereas each binding site alone could not inhibit 
binding of antibody to Tau441 (Fig. 3b). 
  The median intra-assay range-to-average imprecision of one hundred double measurements was 
4.8% (interquartile range 2.4 - 8.9%). Among these duplicate determinations, none resulted in the 
imprecision exceeding 20%, which normally would lead to a repetition of the measurement in the 
everyday diagnostic routine. The results of the inter-assay imprecision are presented in the table 2. The 
comparison of the two reading modes (with- and without wavelength correction) shows clearly better 
precision when the optical density is read out without correction; correspondingly, we used the non-
corrected reading mode for all measurements in this study. 
 
2. Standard curves 
The average OD of the blank sample was 0.067 ± 0.006. The plots of the OD's versus the defined 
concentrations of the standards are presented in the figure 4. The goodness of fit of the average standard 
curve was > 0.99. The CV's of the optical densities obtained in six repetitions of the standard curves were 
between 3.6 - 15.9%. 
  
 
 
3. Inter-center comparison 
The results of the inter-center comparison (averages of the reported concentrations and the corresponding 
coefficients of variation) are presented in the table 3 and, exemplarily for two pairs of samples, in the 
figure 5.  
 
 
 
4. Clinical validation 
The results of the measurements of Non-P-Tau in the patients CSF samples are presented in fig. 6. The 
concentrations were highly significantly increased in the AD/MCI group (109.2 ± 32.0 pg/mL) compared 
to the Controls (62.1 ± 9.3 pg/mL, p<0.001, fig. 6a). At a cut-off of 78.3 mg/mL, the sensitivity and the 
specificity were 94.8% and 97.6%, respectively. The area under the ROC curve (fig. 6b) was 0.976 (95% 
CI: 0.923 to 0.996). 
 
Discussion 
In this paper, we present the development, and the analytical and clinical validation of an assay capable to 
specifically measure the concentrations of non-phosphorylated tau molecules in human CSF. NDD relays 
currently on the analysis of the CSF biomarkers belonging to two groups: amyloid β peptides and tau 
proteins [19]. The latter includes also phosphorylated forms, which emerged from the observation that the 
tau molecule is hyperphosphorylated in tau deposits in the AD brain [10, 20]. Whereas increased CSF 
concentration of tau is a sensitive marker of neurodegeneration, but entirely unspecific for AD, increased 
concentration of pTau molecules seems much more AD specific [21, 22]. On the other hand, virtually 
nothing is known about the possible diagnostic utility of non-phosphorylated tau epitopes. 
 Due to its unfolded, highly hydrophilic nature, tau is a highly phosphorylation-prone protein with 
85 (in case of the longest isoform, i. e. 2N4R) potential phosphorylation sites. In experimental conditions, 
about half of them have been observed to be phosphorylated (currently reviewed in [10]). Its main role is 
to stabilize axonal structures, whereas phosphorylation-dephosphorylation regulates directly its 
association and dissociation from the neuron's microtubules. Under physiologic status, tau contains on 
average two phosphorylated sites; this number can increase to 7-8 sites under pathologic conditions such 
as AD [23]; correspondingly, "phosphorylated tau" is actually a mixture of differently phosphorylated tau 
proteins. 
 By immunization with phosphorylated tau protein, we obtained the monoclonal antibody 1G2 
with a specificity to the TPP sequence in its unphosphorylated form flanked by a basic amino acid at the 
N-terminus. This resulted in three binding sites on 2N4R Tau containing 441 amino acids. Threonine 181 
and threonine 231 are two main phospho-tau positions addressed in the assays utilized for AD 
diagnostics, and providing a similar clinical performance [24]. Here, we chose the unphosphorylated 
T181 and T231 (in addition to T175) epitopes for our novel assay. Binding of 1G2 antibody to Tau441 
increases by availability of free TPP motives (figure 3b) and this characterizes a very strong avidity for 
maximum of three free binding sites. Nevertheless, T175, T181 and T231 are phosphorylated by several 
kinases that are not specific for only one of these positions and it could be assumed that detection of such 
non-phosphorylated tau is not dependent on activity of only one unique kinase. Capturing of this non-
phosphorylated tau from CSF using 1G2 as capture antibody could not be defined as specific for one of 
these three binding sites. pTau181 and pTau231 have been widely described as biomarkers of AD [21, 24, 
25], whereas, to our best knowledge, pTau175 has not been reported so far in the context of its possible 
diagnostic relevance. Based on the results of our analysis we assume that this tau population bound by 
1G2 antibody is rather a minor part of total tau in CSF and we can assume that strongest avidity obtained 
by using two binding sites on a single tau molecule could be a requirement for detection of such low 
concentrations. 
 Analytical validation of the assay revealed its very good performance, with reasonable intra- and 
inter-assay precision, and standard curve repetition, comparable to the parameters observed in other NDD 
assays [26]. Noteworthy is that among duplicate determinations of one hundred patients' samples, none 
resulted in the imprecision exceeding 20%, which would force repetition of the measurement in the 
everyday diagnostic routine. The inter-center study with the paired frozen/non-frozen QC samples 
indicated no differences between the two preanalytical sample handling and shipping procedures: in 
virtually all cases the results obtained from a frozen sample were practically identical, in terms of the 
measured concentrations as well as the imprecision, as the results obtained from a matched sample 
shipped under ambient temperature. We believe this has important practical implication, since patients 
samples can be shipped to a distant laboratory at ambient temperature and without freezing, which 
significantly decreases costs of shipment, at least as long as a sample is delivered within 4-5 days. 
Furthermore, QC samples can be similarly shipped at ambient condition (for example, in the kit). On the 
other hand, similarly to other CSF biomarkers routinely used in AD diagnostics, Non-P-Tau 
measurements characterize currently with relatively high inter-center variability (approximately 30%) 
[27, 28]. This situation definitely should be improved; however, before successful measures are 
undertaken to reduce inter-center variability, establishing center-specific reference ranges for diagnostic 
purposes could help solve the problem of diagnostic-relevant interpretation. 
 To properly interpret the clinical validation results, particularly the ROC curve, Youden Index, 
and the corresponding sensitivity and specificity, it has to be taken into consideration that the NDD 
biomarkers, including Tau and pTau181, were used to classify the patients. This significantly improves 
the categorization of the groups [3, 29]; however, it has a drawback that it biases the estimation of the 
overall diagnostic value of a novel candidate biomarker.  
 We are aware of at least two limitations of our study: (a) in our clinical part, we included only 
patients with AD and non-demented controls. Certainly it would be interested to see if Non-P-Tau could 
be helpful in differential diagnostics of other dementing conditions, particularly tauopathies (for example, 
fronto-temporal lobar degeneration). (b) as already stated, our strategy of patient inclusion relies on the 
application of "classic" NDD biomarkers to support clinical and neuropsychological diagnoses. 
Therefore, a further study with non-NDD biased subjects, whose diagnoses are, for example, confirmed 
by neuropathology, is certainly needed. 
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Figure legends 
Fig. 1. Schematic presentation of the Tau molecule, the three epitopes addressed in this study, and the 
corresponding kinases. 
 
Fig. 2. Epitope mapping of 1G2 antibody on 12 amino acid peptides of 2N4R TAU441 with 10 amino 
acid overlapping. Peptides are spotted on NC membranes 10 amino acids overlapped. Membranes 
blocked with 5% skim milk powder in Tris buffer pH 10 containing 0,1 % Tween 20. After 1 µg/ml 1G2 
was incubated in blocking buffer at room temperature overnight followed by 3 x washing using Tris 
buffer and anti-mouse IgG antibody HRP conjugated. Staining was performed using Western blot staining 
solution based on TMB. Antibody 1G2 binds to peptide sequences containing KTTP or RTTP motiv. 
Spots of these 12 amino acid peptides showing reactivity of 1G2 are described for line 3 and line 4 of the 
NC membrane. 
 
Fig. 3. Specificity of 1G2 antibodies. 
3a. Binding of antibody 1G2 to Tau peptides containing different phosphorylated amino acids coated on 
ELISA plates. Bound 1G2 was detected using anti-mouse-IgG antibody HRP conjugted followed by 
TMB staining.  
3b. Inhibition of Tau441 capturing by 1G2 antibody by competition with different peptides containing 
phosphorylations on 181 and 231 positions. Sandwich ELISA with 1G2 coated on ELISA plates, 
overnight incubation at 2-10°C with Tau441 and competing peptides and detection of captured antigen 
(Tau441) using 7E5 antibody HRP conjugated followed by TMB staining. (The figure left and right panel 
should contain identical names for the peptides i.e non-pTau peptide, pT175 peptide, pT175/181 peptide, 
pT175/181/231 peptide) 
 
Fig. 4. Reproducibility of the standard curves of the assay; presented are average optical densities (OD’s) 
and their standard deviations; the insert presents the zoom-in of the four lowest standards. 
 
Fig. 5. Results of the inter-center variability study: presented are the reported concentrations of two pairs 
of QC samples (A/E and B/F) sent frozen (filled symbols) and under ambient temperature (open 
symbols). 
 
Fig. 6. Non-P-Tau concentrations in the patients' groups, whose clinical and neuropsychological 
diagnoses were supported by the "classic" AD biomarkers. 
6a. Concentrations in the patients' CSF (circles) with medians and inter-quartile ranges (bars). The long 
horizontal bar presents the cut off at the maximal Youden Index. 
6b. Receiver Operating Characteristic Curve. 
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